Form 4: BioCardia Executive Reports Stock Transactions

BioCardia, Inc. executive Edward M. Gillis reported transactions involving common stock and stock options on July 2, 2026.

Summary

• Edward M. Gillis, Senior Vice President, Devices at BioCardia, Inc., reported a transaction on July 2, 2026.
• This transaction involved 17,269 shares of common stock, acquired at a price of $1.24 per share.
• These shares were withheld by the Issuer to satisfy tax obligations related to the net settlement of RSUs that vested on June 29, 2026.
• This does not represent a sale by the reporting person.
• Following this transaction, Gillis beneficially owns 54,126 shares of common stock directly.
• Additionally, Gillis acquired a stock option (right to buy) on July 6, 2026, for 29,442 shares of common stock at an exercise price of $1.20.
• This option vests and becomes exercisable monthly starting August 6, 2026, with full vesting over 48 months, subject to continued service.
• The option has an expiration date of July 6, 2036.
• Following the option acquisition, Gillis beneficially owns 61,139 derivative securities directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents routine insider transactions related to compensation and tax obligations rather than a significant strategic shift or performance indicator.

Positives

• The reporting person continues to hold a significant number of shares (54,126) directly.
• The acquisition of a new stock option for 29,442 shares indicates potential future equity participation and aligns management with company performance.
• The stock option has a long expiration date (July 6, 2036), providing a long-term incentive.

Negatives

• The transaction involving the withholding of shares for tax obligations, while standard, represents a reduction in the net shares available to the executive.
• The exercise price of the new stock option is $1.20, suggesting the current market price or expected future price is around this level.

Risks

• The vesting schedule of the stock option is subject to continued service as a provider, meaning any departure before full vesting would result in forfeiture of unvested options.
• The reliance on stock options as a form of compensation carries inherent market risk; the value of these options is tied to the future stock price of BioCardia, Inc.

Future Outlook

The company has granted a stock option to Edward M. Gillis that vests over 48 months, indicating a long-term incentive structure and expectation of continued service and performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors, detailing changes in their beneficial ownership of company stock. The transactions reported by Edward M. Gillis are typical for a corporate officer, involving the settlement of restricted stock units (RSUs) and the grant of new stock options, reflecting standard compensation and incentive practices within the biotechnology sector.

Stakeholder Impact

• Shareholders: The transactions do not directly indicate a change in the company's fundamental value but reflect standard executive compensation practices. The stock option grant aligns executive interests with long-term shareholder value.
• Employees: The RSU settlement and option grant are part of the executive compensation package, which can influence overall employee morale and retention strategies.
• Management: Edward M. Gillis's beneficial ownership and incentive structure are detailed, providing transparency.

Next Steps

• Monthly vesting of stock options for Edward M. Gillis, starting August 6, 2026, contingent on continued service.
• Continued monitoring of BioCardia, Inc.'s stock performance in relation to the granted stock options.

Key Dates

Keywords

BioCardia, BCDA, Form 4, Stock Option, Common Stock, Beneficial Ownership, Insider Trading, SEC Filing, Edward M. Gillis, RSU Settlement, Vesting Schedule